Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
Michael A Ueberall,1 Ute Essner,2 Gerhard HH Mueller-Schwefe31Institute of Neurological Sciences, 90411 Nuernberg, Germany; 2O.Meany Consultancy, 22339 Hamburg, Germany; 3Interdisciplinary Centre for Pain and Palliative Care Medicine, 73033 Goeppingen, GermanyObjective: To evaluate effectiveness, to...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-05-01
|
Series: | Journal of Pain Research |
Subjects: | |
Online Access: | https://www.dovepress.com/effectiveness-and-tolerability-of-thccbd-oromucosal-spray-as-add-on-me-peer-reviewed-article-JPR |
id |
doaj-d2936a4c593e42549b7bc0f93b55caa9 |
---|---|
record_format |
Article |
spelling |
doaj-d2936a4c593e42549b7bc0f93b55caa92020-11-25T03:34:30ZengDove Medical PressJournal of Pain Research1178-70902019-05-01Volume 121577160445919Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-RegistryUeberall MAEssner UMueller-Schwefe GHHMichael A Ueberall,1 Ute Essner,2 Gerhard HH Mueller-Schwefe31Institute of Neurological Sciences, 90411 Nuernberg, Germany; 2O.Meany Consultancy, 22339 Hamburg, Germany; 3Interdisciplinary Centre for Pain and Palliative Care Medicine, 73033 Goeppingen, GermanyObjective: To evaluate effectiveness, tolerability and safety of an oromucosal spray containing Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as add-on treatment in patients with severe chronic pain (SCP).Methods: Exploratory analysis of anonymized 12-week routine/open-label data provided by the German Pain e-Registry (GPR) on adult SCP patients treated with THC:CBD oromucosal spray in 2017.Results: Among those 30.228 cases documented in the GPR in 2017, 800 (2.6%; 57% female, mean ± SD age: 46.3±9.7 years) received a treatment with THC:CBD. All patients fulfilled the legislative preconditions for a treatment with cannabis as medicine as defined by the German Act Amending Narcotics and Other Regulations. THC:CBD-treatment was followed by an aggregated nine-factor symptom relief (ASR-9) improvement at end of week 12 vs baseline of 39.0±26.5% (95%-CI: 36.9–41.1, median: 42, range −41 to 85). A full ASR-9 response (ie, a 50%-improvement in all 9 factors) was found for 123 patients (15.4%), while 488 patients (56.0%) presented with an ≥50% improvement in at least 5 of 9 ASR factors. With a 54.9±17.2% (median: 56%, range: −6 to 85) improvement was significantly superior in the neuropathic pain subgroup (n=497, 62.1%) vs those with mixed (n=249, 31.1%; ASR-9: 18.2±12.0, median: 19, range: −12 to 42%) or nociceptive pain (n=54, 6.8%; ASR-9: −11.9±10.5, median: −11, range: −41% to 12%; p<0.001 for each). 159 patients (19.9%) reported at least one of 206 TEAEs, most of them of mild intensity (n=81.6%). Most frequently reported TEAEs were increased appetite (n=50, 6.3%) and dysgeusia (n=23, 2.9%). TEAE-related discontinuations were reported for 32 patients (4.0%). 113 (14.1%) patients discontinued due to inadequate pain relief, most of them with nociceptive pain (n=40, 74.1%), least with neuropathic pain (n=1, 0.2%; p<0.001).Conclusion: THC:CBD oromucosal spray proved to be an effective and well-tolerated add-on treatment for patients with elsewhere refractory chronic pain – especially of neuropathic origin.Keywords: THC:CBD spray, add-on treatment, severe chronic pain, neuropathic pain, retrospective analysis, German pain e-Registryhttps://www.dovepress.com/effectiveness-and-tolerability-of-thccbd-oromucosal-spray-as-add-on-me-peer-reviewed-article-JPRTHC:CBD sprayadd-on treatmentsevere chronic painneuropathic pain phenomenologybenefit- risk profileretrospective analysisGerman Pain e-Registry |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ueberall MA Essner U Mueller-Schwefe GHH |
spellingShingle |
Ueberall MA Essner U Mueller-Schwefe GHH Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry Journal of Pain Research THC:CBD spray add-on treatment severe chronic pain neuropathic pain phenomenology benefit- risk profile retrospective analysis German Pain e-Registry |
author_facet |
Ueberall MA Essner U Mueller-Schwefe GHH |
author_sort |
Ueberall MA |
title |
Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry |
title_short |
Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry |
title_full |
Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry |
title_fullStr |
Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry |
title_full_unstemmed |
Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry |
title_sort |
effectiveness and tolerability of thc:cbd oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the german pain e-registry |
publisher |
Dove Medical Press |
series |
Journal of Pain Research |
issn |
1178-7090 |
publishDate |
2019-05-01 |
description |
Michael A Ueberall,1 Ute Essner,2 Gerhard HH Mueller-Schwefe31Institute of Neurological Sciences, 90411 Nuernberg, Germany; 2O.Meany Consultancy, 22339 Hamburg, Germany; 3Interdisciplinary Centre for Pain and Palliative Care Medicine, 73033 Goeppingen, GermanyObjective: To evaluate effectiveness, tolerability and safety of an oromucosal spray containing Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as add-on treatment in patients with severe chronic pain (SCP).Methods: Exploratory analysis of anonymized 12-week routine/open-label data provided by the German Pain e-Registry (GPR) on adult SCP patients treated with THC:CBD oromucosal spray in 2017.Results: Among those 30.228 cases documented in the GPR in 2017, 800 (2.6%; 57% female, mean ± SD age: 46.3±9.7 years) received a treatment with THC:CBD. All patients fulfilled the legislative preconditions for a treatment with cannabis as medicine as defined by the German Act Amending Narcotics and Other Regulations. THC:CBD-treatment was followed by an aggregated nine-factor symptom relief (ASR-9) improvement at end of week 12 vs baseline of 39.0±26.5% (95%-CI: 36.9–41.1, median: 42, range −41 to 85). A full ASR-9 response (ie, a 50%-improvement in all 9 factors) was found for 123 patients (15.4%), while 488 patients (56.0%) presented with an ≥50% improvement in at least 5 of 9 ASR factors. With a 54.9±17.2% (median: 56%, range: −6 to 85) improvement was significantly superior in the neuropathic pain subgroup (n=497, 62.1%) vs those with mixed (n=249, 31.1%; ASR-9: 18.2±12.0, median: 19, range: −12 to 42%) or nociceptive pain (n=54, 6.8%; ASR-9: −11.9±10.5, median: −11, range: −41% to 12%; p<0.001 for each). 159 patients (19.9%) reported at least one of 206 TEAEs, most of them of mild intensity (n=81.6%). Most frequently reported TEAEs were increased appetite (n=50, 6.3%) and dysgeusia (n=23, 2.9%). TEAE-related discontinuations were reported for 32 patients (4.0%). 113 (14.1%) patients discontinued due to inadequate pain relief, most of them with nociceptive pain (n=40, 74.1%), least with neuropathic pain (n=1, 0.2%; p<0.001).Conclusion: THC:CBD oromucosal spray proved to be an effective and well-tolerated add-on treatment for patients with elsewhere refractory chronic pain – especially of neuropathic origin.Keywords: THC:CBD spray, add-on treatment, severe chronic pain, neuropathic pain, retrospective analysis, German pain e-Registry |
topic |
THC:CBD spray add-on treatment severe chronic pain neuropathic pain phenomenology benefit- risk profile retrospective analysis German Pain e-Registry |
url |
https://www.dovepress.com/effectiveness-and-tolerability-of-thccbd-oromucosal-spray-as-add-on-me-peer-reviewed-article-JPR |
work_keys_str_mv |
AT ueberallma effectivenessandtolerabilityofthccbdoromucosalsprayasaddonmeasureinpatientswithseverechronicpainanalysisof12weekopenlabelrealworlddataprovidedbythegermanpaineregistry AT essneru effectivenessandtolerabilityofthccbdoromucosalsprayasaddonmeasureinpatientswithseverechronicpainanalysisof12weekopenlabelrealworlddataprovidedbythegermanpaineregistry AT muellerschwefeghh effectivenessandtolerabilityofthccbdoromucosalsprayasaddonmeasureinpatientswithseverechronicpainanalysisof12weekopenlabelrealworlddataprovidedbythegermanpaineregistry |
_version_ |
1724558564304879616 |